Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Biomea Fusion, Inc.BMEA · Entity 6606 | Chief Medical Officer | May 31, 2024 | June 12, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Biomea Fusion, Inc.
Report date May 31, 2024 · Filed June 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 349 |
Reported balance
After 2024-05-31 transaction · row 1
1 source rowRow 1 · 2024-05-31 · Grant · Acquired 349 · Balance 349 F1: These shares were acquired under the Biomea Fusion, Inc. 2021 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). F2: In accordance with the ESPP, these shares were purchased at a purchase price of 85% of the fair market value of the Issuer's common stock on May 31, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired under the Biomea Fusion, Inc. 2021 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2: In accordance with the ESPP, these shares were purchased at a purchase price of 85% of the fair market value of the Issuer's common stock on May 31, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 31, 2024 Filed Jun 12, 2024 20:30 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantCommon Stock | 349 | $8.94 | $3,120.76 |
DisclosureSEC source: 0000950170-24-072493 · ownership.xml · nonDerivative · entry 1 Frias Juan Pablo · CIK 0001990665 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 349 F1 · kind: These shares were acquired under the Biomea Fusion, Inc. 2021 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at a purchase price of 85% of the fair market value of the Issuer's common stock on May 31, 2024. Read SEC document |
| January 17, 2024 Filed Jan 18, 2024 21:30 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantStock Option (Right to Buy) · Derivative | 111,090 | $0.00 Strike: $14.44 | $0.00 |
DisclosureSEC source: 0000950170-24-005414 · ownership.xml · derivative · entry 1 Frias Juan Pablo · CIK 0001990665 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,090 Underlying: Common Stock · 111,090 shares Expires 2034-01-16 F1 · derivative.exercise_date: The option shall vest and become exercisable in quarterly installments over four years, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| August 31, 2023 Filed Sep 1, 2023 21:10 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $16.87 | $0.00 |
DisclosureSEC source: 0000950170-23-046099 · ownership.xml · derivative · entry 1 Frias Juan Pablo · CIK 0001990665 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2033-08-30 F1 · derivative.exercise_date: One-sixteenth (1/16th) of the total number of shares subject to the stock option shall vest and become exercisable at the end of the third month following August 31, 2023 and one-sixteenth (1/16th) of the total number of shares subject to the stock option shall vest and become exercisable quarterly thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.